Sun Pharma Advanced Research Company Ltd Technical Momentum Shifts Amid Bearish Trends

Current Price and Market Context

As of 31 Dec 2025, SPARC closed at ₹134.45, up 0.52% from the previous close of ₹133.75. The stock traded within a range of ₹131.65 to ₹134.85 during the day, remaining well below its 52-week high of ₹208.35 and above the 52-week low of ₹109.20. This price action reflects a cautious recovery attempt amid a broader downtrend.

Technical Trend Overview

The overall technical trend for SPARC has shifted from outright bearish to mildly bearish, indicating some easing of downward momentum but no definitive reversal yet. On a daily scale, moving averages remain bearish, suggesting that short-term price action is still under pressure. However, weekly indicators such as the MACD and KST have turned mildly bullish, hinting at potential stabilisation or a nascent uptrend.

MACD Analysis

The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On the weekly chart, the MACD is mildly bullish, signalling that momentum could be improving in the near term. Conversely, the monthly MACD remains bearish, reflecting persistent weakness over a longer horizon. This divergence suggests that while short-term momentum may be gaining, the broader trend remains under strain.

RSI and Momentum Indicators

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no clear signal, hovering in neutral territory. This indicates neither overbought nor oversold conditions, implying that the stock is consolidating and awaiting a catalyst for directional movement. The KST (Know Sure Thing) indicator aligns with the MACD, showing mild bullishness weekly but bearishness monthly, reinforcing the theme of short-term improvement amid longer-term caution.

Bollinger Bands and Volatility

Bollinger Bands on both weekly and monthly charts are mildly bearish, suggesting that volatility remains skewed towards downside risk. The bands have not contracted significantly, indicating that price fluctuations are still relatively wide and the stock has not entered a tight consolidation phase. This volatility profile may pose challenges for traders seeking clear breakout opportunities.

On-Balance Volume and Dow Theory Signals

On-Balance Volume (OBV) is bullish on the weekly timeframe, signalling that buying volume is supporting recent price gains. However, monthly OBV shows no clear trend, indicating that longer-term accumulation or distribution is uncertain. Dow Theory assessments mirror this pattern, with weekly signals mildly bullish but monthly signals remaining bearish, underscoring the mixed technical environment.

Comparative Performance Versus Sensex

SPARC’s price performance has lagged significantly behind the broader market benchmark, the Sensex. Year-to-date, the stock has declined by 32.86%, while the Sensex has gained 8.36%. Over the past year, SPARC’s return is down 32.66% compared to the Sensex’s 8.21% gain. Longer-term returns are even more stark, with a 10-year loss of 60.32% against the Sensex’s 226.18% rise. This underperformance highlights structural challenges within the company or sector that technical indicators alone cannot fully capture.

Moving Averages and Daily Momentum

Daily moving averages remain bearish, with the stock trading below key averages such as the 50-day and 200-day moving averages. This technical positioning suggests that short-term selling pressure persists, and any rallies may face resistance near these levels. The bearish daily moving averages contrast with the mildly bullish weekly MACD and KST, indicating a potential lag in short-term price recovery.

Technical Ratings and Market Sentiment

MarketsMOJO assigns SPARC a Mojo Score of 6.0 and a Mojo Grade of Strong Sell as of 1 Feb 2024, an upgrade from the previous Sell rating. This reflects a cautious stance, acknowledging some improvement in technical parameters but maintaining a negative overall outlook. The Market Cap Grade stands at 3, indicating moderate market capitalisation relative to peers in the Pharmaceuticals & Biotechnology sector.

Sector and Industry Context

Within the Pharmaceuticals & Biotechnology sector, SPARC’s technical signals are somewhat out of sync with broader industry trends, where many peers have shown more robust recoveries. The stock’s persistent underperformance relative to the Sensex and sector benchmarks suggests company-specific challenges, possibly related to research pipeline delays, regulatory hurdles, or competitive pressures.

Investor Implications and Outlook

Investors should approach SPARC with caution given the mixed technical signals and significant underperformance relative to the broader market. The mildly bullish weekly momentum indicators offer some hope for a stabilisation or gradual recovery, but the persistent bearish monthly signals and daily moving averages suggest that any upside may be limited or short-lived without fundamental improvements.

Given the stock’s current price of ₹134.45, well below its 52-week high, and the strong sell rating from MarketsMOJO, investors may prefer to monitor technical developments closely before committing fresh capital. The neutral RSI readings imply that the stock is not yet oversold, reducing the likelihood of an imminent sharp rebound.

Summary of Technical Indicators

To summarise, SPARC’s technical landscape is characterised by:

• Weekly MACD and KST mildly bullish, signalling tentative momentum improvement


• Monthly MACD and KST remain bearish, indicating longer-term weakness


• RSI neutral on weekly and monthly charts, showing no extreme conditions


• Bollinger Bands mildly bearish, reflecting ongoing volatility and downside risk


• Daily moving averages bearish, suggesting short-term selling pressure


• OBV bullish weekly but no clear monthly trend, indicating mixed volume support


• Dow Theory mildly bullish weekly but bearish monthly, reinforcing mixed signals

These factors combine to create a complex technical picture that requires careful monitoring and a balanced approach to risk management.

Conclusion

Sun Pharma Advanced Research Company Ltd’s technical parameters reveal a stock at a crossroads, with short-term momentum showing signs of mild improvement but longer-term trends still firmly bearish. The divergence between weekly and monthly indicators highlights the importance of timeframe in technical analysis and suggests that investors should remain vigilant for confirmation of a sustained trend reversal before increasing exposure.

Given the stock’s significant underperformance relative to the Sensex and the strong sell rating from MarketsMOJO, cautious investors may consider alternative opportunities within the Pharmaceuticals & Biotechnology sector or broader market until clearer technical and fundamental signals emerge.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today